Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.2% - Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s stock price fell 6.2% during trading on Monday . The company traded as low as $8.11 and last traded at $8.22. 1,168,915 shares changed hands during trading, a decline of 36% from the average session volume of 1,822,119 shares. The stock had previously closed at $8.76.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DYN. Evercore ISI began coverage on shares of Dyne Therapeutics in a report on Thursday, May 29th. They set an "outperform" rating and a $46.00 price target on the stock. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target on the stock. Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Tuesday, June 17th. JPMorgan Chase & Co. lowered their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Finally, Sanford C. Bernstein began coverage on shares of Dyne Therapeutics in a research report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.13.

Dyne Therapeutics Price Performance

The firm has a market capitalization of $929.82 million, a P/E ratio of -2.28 and a beta of 1.08. The company's 50-day simple moving average is $11.63 and its two-hundred day simple moving average is $13.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DYN. Bank of New York Mellon Corp increased its stake in shares of Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after purchasing an additional 698 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in shares of Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Dyne Therapeutics by 5.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after purchasing an additional 1,115 shares in the last quarter. E Fund Management Co. Ltd. increased its stake in shares of Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after purchasing an additional 1,249 shares in the last quarter. Finally, Arizona State Retirement System increased its stake in shares of Dyne Therapeutics by 9.2% in the first quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock worth $183,000 after purchasing an additional 1,481 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.